ABBOTINDIA

Abbott India – Strong Pharma Franchise Backed by Consistent Growth & High Margins

Abbott India remains a strong play on India’s growing healthcare and chronic therapy market. The company has a strong portfolio in gastro, diabetes, thyroid and anti-infective segments, supported by a trusted global parent brand and wide doctor reach. Financially, the company continues to deliver steady growth with healthy margins and strong cash generation. FY25 revenue rose to ₹6,409 crore while net profit increased 17.7% YoY to ₹1,414 crore. Q4FY25 PAT jumped 28% YoY to ₹367 crore with revenue growth of 11.5%. Abbott India is also known for consistent dividend payouts and an asset-light business model, resulting in high return ratios and low debt. Recent quarters showed continued momentum, with Q2 FY26 revenue growing 7.7% YoY and EBITDA margins expanding to 28.6%. Key Positives: • Strong brand equity in Indian pharma • Leadership in chronic therapies • Consistent profit & margin growth • Debt-light balance sheet with strong cash flows • Healthy dividend track record Abbott India suits long-term investors seeking stability, quality earnings and defensive exposure in the healthcare sector.